Oral Diagnosis Departament, Piracicaba Dental School, Universidade Estadual de Campinas, Piracicaba, São Paulo, Brazil.
Department of Diagnosis in Pathology and Oral Medicine, Molecular Pathology area, School of Dentistry, Universidad de la República, Montevideo, Uruguay.
Sci Rep. 2024 Nov 16;14(1):28303. doi: 10.1038/s41598-024-78763-y.
The present investigation aimed to assess the safety of photobiomodulation (PBM) on the oral carcinogenesis process induced by 4NQO, focusing on cell proliferation and apoptosis. Sixty-six Wistar rats received systemic 4NQO for 12 (n = 33) and 20 weeks (n = 33), divided into Control group, PBM 0.3 J, and PBM 1 J. Applications for PBM occurred three times a week. At weeks 12 and 20, the animals were euthanized. The immunoreactivity for anti-ROS1 and anti-p53 antibodies was also assessed. Statistical analysis was assessed by multiple t-tests, Kruskal-Wallis, and Spearman's correlation. At 12 weeks, PBM 1 J group had nodular lesions, distinct from control and PBM 0.3 J groups (p = 0.005). At 20 weeks, nodular lesions were common in control and PBM 0.3 J groups. Histopathological characteristics did not significantly differ between groups at 12 (p = 0.30) and 20 weeks (p = 0.58). Epithelial dysplasia (n = 21) was common at 12 weeks. After 20 weeks, most of the cases revealed squamous cell carcinoma (n = 24). No differences were observed in the immunostaining of p53 and ROS1 among the control and experimental groups and there was no correlation of these proteins with clinicopathological data. During the carcinogenesis process, the PBM did not modify the development of oral lesions and the expression of proliferative and apoptosis proteins.
本研究旨在评估光生物调节(PBM)对 4NQO 诱导的口腔癌变过程的安全性,重点关注细胞增殖和凋亡。66 只 Wistar 大鼠接受全身 4NQO 处理 12(n=33)和 20 周(n=33),分为对照组、PBM 0.3 J 和 PBM 1 J。每周应用 PBM 三次。在第 12 和 20 周,处死动物。还评估了抗 ROS1 和抗 p53 抗体的免疫反应性。统计分析采用多个 t 检验、Kruskal-Wallis 和 Spearman 相关分析。在 12 周时,PBM 1 J 组出现结节性病变,与对照组和 PBM 0.3 J 组明显不同(p=0.005)。在 20 周时,对照组和 PBM 0.3 J 组常见结节性病变。12 周(p=0.30)和 20 周(p=0.58)时,各组的组织病理学特征无显著差异。12 周时上皮异型增生(n=21)常见。20 周后,大多数病例显示鳞状细胞癌(n=24)。对照组和实验组的 p53 和 ROS1 免疫染色无差异,这些蛋白与临床病理数据无相关性。在癌变过程中,PBM 并未改变口腔病变的发展和增殖及凋亡蛋白的表达。